EBV阳性弥漫大B细胞淋巴瘤(非特指型):2020诊断、风险分层与管理更新
EBV阳性弥漫大B细胞淋巴瘤(非特指型)是2016年WHO分类中的侵袭性B细胞淋巴瘤,与慢性EBV感染相关,标准化疗预后差。诊断依赖病理评估和EBER检测,但阳性截断值未定。风险分层可用IPI和Oyama评分,CD30和PD-1/PD-L1是潜在不良但可靶向的生物标志物。管理应遵循EBV阴性DLBCL指南,但预后可能更差,靶向治疗有待研究。
要点
- EBER检测是诊断标准,但阳性截断值尚未明确。
- IPI和Oyama评分(年龄>70岁和B症状)可用于风险分层。
- CD30和PD-1/PD-L1表达是潜在不良但可靶向的生物标志物。
核心结论
- EBV阳性DLBCL,NOS是侵袭性淋巴瘤,标准化疗预后差,靶向治疗待研究。
主要发现
- EBV阳性DLBCL,NOS与慢性EBV感染相关,标准化疗预后差。
- CD30和PD-1/PD-L1表达是潜在不良但可靶向的生物标志物。
- 在化学免疫治疗时代,EBV阳性DLBCL可能比EBV阴性预后更差。
关键数值与推荐
- 诊断需病理评估,EBER检测为标准,但阳性截断值未定义。
- 风险分层可用IPI和Oyama评分(年龄>70岁和B症状)。
临床怎么用
- EBV阳性DLBCL,NOS应按EBV阴性DLBCL类似指南进行分期和管理。
- 可考虑评估CD30和PD-1/PD-L1表达作为潜在靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Epstein Barr virus-positive (EBV+) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) is an entity included in the 2016 WHO classification of lymphoid neoplasms. EBV+ DLBCL, NOS, is an aggressive B-cell lymphoma associated with chronic EBV infection, and a poor prognosis with standard chemotherapeutic approaches. DIAGNOSIS: The diagnosis is made through a careful pathological evaluation. Detection of EBV-encoded RNA (EBER) is considered standard for diagnosis; however, a clear cutoff for positivity has not been defined. The differential diagnosis includes plasmablastic lymphoma (PBL), DLBCL associated with chronic inflammation and primary effusion lymphoma (PEL), among others. RISK-STRATIFICATION: The International Prognostic Index (IPI) and the Oyama score can be used for risk-stratification. The Oyama score includes age >70 years and presence of B symptoms. The expression of CD30 and PD-1/PD-L1 are emerging as potential adverse but targetable biomarkers. MANAGEMENT: Patients with EBV+ DLBCL, NOS, should be staged and managed following similar guidelines than patients with EBV-negative DLBCL. EBV+ DLBCL, NOS, however, might have a worse prognosis than EBV-negative DLBCL in the era of chemoimmunotherapy. There is an opportunity to study and develop targeted therapy in the management of patients with EBV+ DLBCL, NOS.
引用
- Beltran BE, Castro D, Paredes S, et al. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020. PMID: 32072672. doi:10.1002/ajh.25760
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。